Use our assays to predict drug response based on the presence of a
G1/S deficit (cellular or lymphocyte test) and particular genetic mutations
(genetic tests).

Develop companion diagnostics by using our tests as patient-drug
selection assays to predict patients’ responses to AD drugs. Drug
selection can be personalized according to G1/S deficits measured by
our lymphocyte test and genetic tests together, or by refinement of our
lymphocyte test alone. Companion diagnostics might also be used to
expand indications to include presymptomatic (MCI) patients with G1/S
cell cycle deficits. If you are planning a clinical trial, contact us about the
development of a companion diagnostic product to encourage clinical use
of your drug and support premium pricing..

.